Home-spirometry exacerbation profiles in children with cystic fibrosis.
antibiotic
cystic fibrosis
exacerbation
pediatrics
spirometry
telemedicine
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
revised:
01
11
2023
received:
26
05
2023
accepted:
17
11
2023
medline:
28
11
2023
pubmed:
28
11
2023
entrez:
28
11
2023
Statut:
aheadofprint
Résumé
Pulmonary exacerbations (PEx) are strong predictors of respiratory disease progression in children with cystic fibrosis (CwCF) and may be associated with persistent decreased lung function after acute management. Telemonitoring devices can be used for early detection and monitoring of PEx, but its utility is debated. Which symptoms and telemonitoring spirometry characterics are related to outcome dynamics following initial PEx management? This retrospective study included CwCF followed at Bordeaux University Hospital, France. All severe PEx episodes treated with intravenous (IV) antibiotics (ATB) between 1 January 2017 and 31 December 2021 in CwCF using home telemonitoring were analyzed. Symptoms and home spirometry data were collected 45 days before and up to 60 days after each IV ATB course. We defined three response profiles based on terciles of baseline forced expiratory volume in 1 s (FEV A total of 346 IV ATB courses for PEx were administered to 65 CwCF during the study period. The drop in FEV Home spirometry may facilitate the early recognition of PEx to implement earlier interventions. This study also provides an outcome lung function threshold which identifies low responders to IV ATB.
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary exacerbations (PEx) are strong predictors of respiratory disease progression in children with cystic fibrosis (CwCF) and may be associated with persistent decreased lung function after acute management. Telemonitoring devices can be used for early detection and monitoring of PEx, but its utility is debated.
RESEARCH QUESTION
OBJECTIVE
Which symptoms and telemonitoring spirometry characterics are related to outcome dynamics following initial PEx management?
METHODS
METHODS
This retrospective study included CwCF followed at Bordeaux University Hospital, France. All severe PEx episodes treated with intravenous (IV) antibiotics (ATB) between 1 January 2017 and 31 December 2021 in CwCF using home telemonitoring were analyzed. Symptoms and home spirometry data were collected 45 days before and up to 60 days after each IV ATB course. We defined three response profiles based on terciles of baseline forced expiratory volume in 1 s (FEV
RESULTS
RESULTS
A total of 346 IV ATB courses for PEx were administered to 65 CwCF during the study period. The drop in FEV
INTERPRETATION
CONCLUSIONS
Home spirometry may facilitate the early recognition of PEx to implement earlier interventions. This study also provides an outcome lung function threshold which identifies low responders to IV ATB.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Aadairc
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7:450-453.
Santo AH, da Silva-Filho LVRF. Cystic fibrosis-related mortality trends in Brazil for the 1999-2017 period: a multiple-cause-of-death study. J Bras Pneumol. 2021;47:e20200166.
Martin C, Hamard C, Kanaan R, et al. Causes of death in French cystic fibrosis patients: the need for improvement in transplantation referral strategies! J Cyst Fibros. 2016;15:204-212.
O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891-1904.
Caverly LJ, VanDevanter DR. The elusive role of airway infection in cystic fibrosis exacerbation. J Pediatric Infect Dis Soc. 2022;11:S40-S45.
Wagener JS, VanDevanter DR, Konstan MW, Pasta DJ, Millar SJ, Morgan WJ. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Pediatr Pulmonol. 2020;55:828-834.
Waters VJ, Stanojevic S, Sonneveld N, et al. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros. 2015;14:755-762.
Sanders DB, Bittner RCL, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182:627-632.
Stephen MJ, Long A, Bonsall C, et al. Daily spirometry in an acute exacerbation of adult cystic fibrosis patients. Chron Respir Dis. 2018;15:258-264.
Sanders DB, Hoffman LR, Emerson J, et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol. 2010;45:127-134.
West NE, Beckett VV, Jain R, et al. Standardized treatment of pulmonary exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations. J Cyst Fibros. 2017;16:600-606.
Abbott L, Plummer A, Hoo ZH, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev. 2019;9:CD006682.
Nicholson TT, Smith A, McKone EF, Gallagher CG. Duration of intravenous antibiotic treatment for acute exacerbations of cystic fibrosis: a systematic review. J Cyst Fibros. 2022;21(4):562-573. doi:10.1016/j.jcf.2021.08.017
Schechter MS. Reevaluating approaches to cystic fibrosis pulmonary exacerbations. Pediatr Pulmonol. 2018;53:S51-S63.
Vagg T, Shanthikumar S, Morrissy D, Chapman WW, Plant BJ, Ranganathan S. Telehealth and virtual health monitoring in cystic fibrosis. Curr Opin Pulm Med. 2021;27:544-553.
Dixon E, Dick K, Ollosson S, et al. Telemedicine and cystic fibrosis: do we still need face-to-face clinics? Paediatr Respir Rev. 2022;42:23-28.
Lechtzin N, Mayer-Hamblett N, West NE, et al. Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations. eICE study results. Am J Respir Crit Care Med. 2017;196:1144-1151.
van Horck M, Winkens B, Wesseling G, et al. Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function. Sci Rep. 2017;7:12350.
Beaufils F, Enaud R, Gallode F, et al. Adherence, reliability, and variability of home spirometry telemonitoring in cystic fibrosis. Front Pediatr. 2023;11:1111088.
Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. Am Rev Respir Dis. 1976;113:587-600.
Bouzek DC, Ren CL, Thompson M, Slaven JE, Sanders DB. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis. Pediatr Pulmonol. 2022;57:1709-1716.
Heltshe SL, West NE, VanDevanter DR, et al. Study design considerations for the standardized treatment of pulmonary exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF. Contemp Clin Trials. 2018;64:35-40.
Goss CH, Heltshe SL, West NE, et al. A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. Am J Respir Crit Care Med. 2021;204:1295-1305.
Waters V, Stanojevic S, Klingel M, et al. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J Cystic Fibros. 2015;14:770-776.
Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2000;3:CD001021.
Sequeiros IM, Jarad N. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis. Chron Respir Dis. 2012;9:9-16.